Media stories about Cerulean Pharma (NASDAQ:DARE) have been trending somewhat positive on Wednesday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cerulean Pharma earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.8617265746502 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Cerulean Pharma (DARE) opened at $2.48 on Wednesday. Cerulean Pharma has a one year low of $2.24 and a one year high of $35.80.

ILLEGAL ACTIVITY WARNING: “Cerulean Pharma (DARE) Earns Daily Media Sentiment Rating of 0.16” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/12/06/cerulean-pharma-dare-earns-daily-media-sentiment-rating-of-0-16.html.

About Cerulean Pharma

Dare Bioscience, Inc, formerly Cerulean Pharma Inc, is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse.

Insider Buying and Selling by Quarter for Cerulean Pharma (NASDAQ:DARE)

Receive News & Stock Ratings for Cerulean Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma Inc. and related stocks with our FREE daily email newsletter.